You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of January 30, 2018

  • Discovery Projects
  • Phase 1
    12
  • Phase 2
    5
  • Phase 3
    19
  • Registration
    3
  • Total39
 
Compound Name
Indicationsort descending
Phase
Submission Type
Compound Type
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Platinum Resistant/Refractory Ovarian Cancer (Biologic) Phase 3 Product Enhancement Biologic
Sutent (sunitinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Multiple Tyrosine Kinase Inhibitor
Go to clinical trial
Renal Cell Carcinoma Adjuvant (E.U.) Registration Product Enhancement Small Molecule
Inlyta (axitinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
VEGF Tyrosine Kinase Inhibitor
Go to clinical trial
Renal Cell Carcinoma Adjuvant, *Cancer combo w/ Merck's Keytruda (PD-1, pembrolizumab) Phase 3 Product Enhancement Small Molecule
  •  
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options